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Abstract
Goals of work The aim of this study was to evaluate pain
intensity and the application of the WHO guidelines for
cancer pain treatment in patients with prostate cancer
treated at Swiss cancer centers.
Materials and methods We analyzed a series of five
multicenter phase II clinical trials which examined the
palliative effect of different chemotherapies in patients with
advanced hormone-refractory prostate carcinoma. Of 170
patients, 1,018 visits were evaluable for our purpose,
including ratings of pain intensity by patients and pre-
scribed analgesics.
Main results No or mild pain was indicated by patients in 36
to 55% of the visits, more than mild pain in 30 to 46%. In 21%
of the visits, the WHO pain treatment criteria (treatment
according to one of the three steps; oral, rectal or transdermal
application of the main dose; administration on a regular
schedule) were fulfilled, and the Cleeland index was positive
according to all recommendations. In 6% of the visits, neither
the WHO criteria were fulfilled nor was the Cleeland index
positive. This indicates insufficient pain treatment not follow-
ing the WHO guidelines and that the prescribed analgesics
were not sufficiently potent for the rated pain intensity.
Conclusions In this selective Swiss sample, the standard of
analgesic treatment is high. However, there is still scope for
improvement. This cannot solely be solved by improving
the knowledge of the physicians. Programs to change the
patients’ attitude towards cancer pain, training to improve
the physicians’ communication skills, and institutional
changes may be promising strategies.
Keywords Prostate cancer . Pain . Analgesic treatment .
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Introduction
Prostate cancer is the most commonly diagnosed male
cancer and is likely to become even more important mainly
because of the increasing number of elderly people in the
population and probably because of improved surveillance
and early diagnosis [17]. With a 5-year survival rate of
75%, it is one of the cancers with a favorable prognosis.
Nevertheless, prostate cancer in advanced stages remains a
disease with few therapeutic options. In primarily localized
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disease, metastases develop in 30 to 50% [12, 14, 29] and
are already present at the time of diagnosis in 15 to 25% of
patients. Metastatic prostate cancer involves many organs,
but the skeleton is most frequently involved with 84% or
more of distant metastases. Pain is the primary symptom of
metastatic disease, occurring in 50 to 75% of patients [3, 9,
16] or even more [5]. Severe pain does not only cause
enormous suffering, it also leads to impairment in the
activities of daily living, to psychological, familial, and
professional dysfunction and disturbance of sleep, appetite,
and vitality [11, 26]. Thus, analgesic treatment is a major
aim in these patients.
In 1986, the World Health Organization (WHO) started a
worldwide campaign for cancer pain relief, proposing
guidelines on effective use of drugs to treat cancer pain,
based on ample clinical and empirical experience. The
proposed three-step treatment is simple and efficacious
[27]. Are these guidelines really applied in clinical routine?
Former investigations showed that 40 to 50% of patients
with cancer pain receive insufficient analgesic therapy
despite these guidelines [2, 7, 26, 28].
In this study, we retrospectively investigated the situa-
tion in Switzerland by analyzing a series of five multicenter
phase II clinical trials which examined the palliative effect
of different chemotherapies in patients with advanced
hormone-refractory prostate carcinoma [15, 20–22, 24].
Only patients treated at major Swiss cancer centers, where
optimal treatment can be expected, were included in this
study. Their pain intensity and individual analgesic treat-
ment were recorded from enrollment into the trial until
chemotherapy was stopped (e.g., due to tumor progression,
severe toxicity). In contrast, most other reports on analgesic
treatment in cancer patients have been based on cross-
sectional analyses [4, 25] or examined shorter periods, e.g.,
as long as the patients were hospitalized [1, 2, 6, 18, 28].
Materials and methods
The SAKK trials
From 1991 to 2001, the Swiss Group for Clinical Cancer
Research (SAKK) has conducted five phase II trials of various
chemotherapeutics in patients with hormone-refractory ad-
vanced prostate cancer within the framework of a master
protocol [15, 20–22, 24]. For the evaluation of palliative
benefit, pain intensity and pain treatment were recorded in
addition to clinical endpoints. All patients received a
chemotherapy according to the corresponding trial protocol.
Analgesic therapy was prescribed individually.
The inclusion criteria were similar in all five trials:
histologically or cytologically proven prostate cancer,
advanced disease with metastases, documented progression
under previous endocrine therapy, life expectancy of at least
3 months, sufficient bone marrow reserve, adequate liver
and renal function, continuation of LH-RH analogues;
antiandrogens stopped at least 1 month before enrollment
[20–22] or before chemotherapy was given [24], radiother-
apy stopped at least 3 [20] or 4 weeks [15, 21, 22, 24]
before enrollment, no previous chemotherapy (except in the
first trial [15]).
First trial (SAKK 08/91; 1991–1993)
Carboplatin was administered [15]. Inclusion criteria not
mentioned above: WHO performance status ≤3 (range 0–4),
measurable tumor lesions or WHO pain index ≥2 [range 0
(no pain)–4]. There was no upper age limit. Four of the 28
patients had previous chemotherapy. Endocrine therapy had
to be continued during the trial treatment. Treatment was
stopped if there was a subjective or objective assessment of
tumor progression (i.e., treatment failure), unexpected
severe toxicities, refusal by the patient, or any other serious
medical complication.
Second trial (SAKK 08/93; 1993–1995)
Oral Idarubicin was administered [24]. Patients older than
80 years or with severe heart disease were excluded. A
maximum of 11 cycles was allowed. Treatment was
stopped in case of patient refusal, deterioration of renal or
hepatic function, toxicities of grade 3 or 4 according to
WHO criteria, or progression of disease.
Third trial (SAKK 08/95; 1995-1997)
Gemcitabine was administered [20]. Upper age limit was
80 years. WHO performance status had to be ≤2 and
prostate-specific antigen (PSA) level at least three times the
upper normal level. Treatment was stopped after ten cycles
or in case of tumor progression (according to PSA levels,
progression of known lesions or appearance of new
metastases on X-rays or bone scans), unexpected severe
toxicities, refusal by patient or any other serious medical
complication.
Fourth trial (SAKK 08/97; 1997–1999)
Vinorelbine was administered [22]. Upper age limit was
85 years. Patients with known leptomeningeal or brain
metastases were excluded. WHO performance status had to
be ≤2 and PSA level at least three times the upper normal
level. A maximum of 12 cycles was administered.
Treatment was stopped in case of patient refusal, unaccept-
able toxicity or tumor progression (new lesions, increase of
measurable lesions or PSA progression).
462 Support Care Cancer (2008) 16:461–467
Fifth trial (SAKK 08/00; 2000–2001)
Capecitabine was administered [21]. Upper age limit was
85 years. Patients with known brain metastases were
excluded. WHO performance status had to be ≤2 and
PSA level ≥5 ng/ml. A maximum of eight cycles was
administered. Treatment was stopped when there was PSA
progression or documented clinical progression.
Assessment of pain intensity
Pain intensity was one of several quality of life domains
assessed by the patients based on the EORTC questionnaire
(EORTC QLQ-C30). The scale had a range from 1 to 4
(“not at all”, “a little”, “quite a bit”, “very much”). The time
frame was related to the past week. This assessment was
made on each visit to the hospital (at baseline, on day 8 of
the first chemotherapy cycle, and day 1 of each following
cycle) until treatment failure.
Assessment of pain treatment
For every visit, we investigated whether the analgesic
treatment was administered according to three criteria of the
WHO guidelines: Three-step treatment (starting with an
NSAID or paracetamol, adding a weak opioid such as
tramadol in the second step, and a strong opioid such as
morphine in the third step); mainly oral, rectal, or
transdermal administration; regular administration “around
the clock”, i.e., at fixed time intervals. The application
according to the drugs’ pharmacokinetics could not be
evaluated. Based on clinical experience, our primary
hypothesis was that the WHO analgesic ladder was not
followed. In particular, we hypothesized that the opioids
were prescribed without addition of paracetamol or
NSAID.
For a summary evaluation, we analyzed for all visits
whether or not the patients were treated according to the
WHO pain treatment criteria, as defined above (yes/no).
“Yes” was assigned if all of the three WHO pain treatment
criteria were fulfilled.
In addition, for purpose of consistency, we calculated the
Cleeland pain management index for every visit [4]. This
index compares the most potent analgesic prescribed for that
patient with the patient’s reported level of pain. Four levels
of analgesic therapy are defined: 0, no analgesic drug; 1, a
non-opioid (e.g., a NSAID); 2, a weak opioid; 3, a strong
opioid (e.g., morphine). In addition, four levels of pain are
defined, in correspondence with our patient-rated pain scale:
0, absence of pain; 1, mild pain; 2, moderate pain; and 3,
severe pain. The pain management index is calculated by
subtracting the pain level from the analgesic level and ranges
from −3 (a patient with severe pain receiving no analgesic
drugs) to +3 (a patient reporting no pain receiving morphine
or an equivalent). Negative scores are considered to indicate
inadequate orders for analgesic drugs, and scores of 0 or
higher are considered to be a conservative indicator of
acceptable treatment.
Statistical analysis
Pain intensity and treatment were presented by descriptive
statistics or frequency counts. All analyses were carried out
for the whole dataset and for two subsets stratified by
patient-rated pain intensity: visits with less pain (EORTC
pain score=0 “not at all” or=1 “a little”) vs visits with
substantial pain (EORTC pain score=3 “quite a bit” or=4
“very much”). This grouping is consistent with the results
by Serlin et al. [25] who showed a consistent pattern of pain
interference as a function of pain severity.
Results
Sample description and patient characteristics
Overall, 170 patients and 1,018 visits were evaluable for
our purpose. The number of visits varied from 132 to 252
per trial. Across all trials, the median number of visits per
patient was between six (minimum/maximum over all
trials: 2/15).
Pain treatment documented by the physician was
available for all visits. However, some of the items were
not answered or the response was considered invalid: WHO
step 2% (n=22), administration route 5% (n=49), admin-
istration schedule 5% (n=51), and physician-rated pain 3%
(n=28). Patient-rated pain was available for 85% of the
visits (n=870). Fulfillment of WHO pain treatment criteria
could not be calculated for visits in which patients received
no analgesics (271 visits or 27% of all visits).
The patients’ characteristics at baseline are summarized
in Tables 1 and 2. Because of the similar inclusion criteria,
the trial samples are homogeneous: most of the patients had
bone metastases, a performance status of 0 or 1 (exception:
first trial); in all trials, the median age was between 68 and
72 years. The patient-rated pain intensity at baseline varied
from 41% of patients indicating more than mild pain [22]
up to 71% [15].
Pain intensity
Overall, in 262 visits (26%), the patients indicated no pain,
in 242 visits (24%) “a little” pain, in 248 visits (24%) “quite
a bit” pain and in 125 visits (12%) “very much” pain,
corresponding to 373 visits (37%) with more than mild pain.
For the individual trials, no or mild pain was indicated in 36
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to 55% of the visits, more than mild pain was indicated in 30
to 46%.
Treatment according to the WHO steps
In 539 visits (53%), the analgesics were administered
according to the three WHO steps: 25% WHO step I with
NSAID and/or paracetamol, 10% WHO step II with weak
opioids, and 18% WHO step III with strong opioids. In 29%
of the 539 visits, adjuvant drugs were added to classical
analgesics. In further 159 visits (16%), weak or strong
opioids were prescribed without NSAID/Paracetamol. In 27
visits (3%), only adjuvant drugs were prescribed. Table 3
shows the analgesic treatment of the two subsets (no or mild
pain, more than mild pain). Overall, opioids were prescribed
in 439 visits (43%) and in 58% of visits of patients indicating
more than mild pain. In 64% of these 439 visits, the opioids
were combined with paracetamol and/or NSAID.
Administration route
In 657 visits (65%), at least one basic medication was
administered orally, in five visits (0.5%) rectally, in 31 visits
(3%) in a transdermal system, in three visits (0.3%)
subcutaneously, and in 2 visits (0.2%) peridurally, never
intravenously. The only relevant change between the trials
was an increase in the use of transdermal systems from 0%
in the first to 11% in the most recent trial. In patients with
more than mild pain, there were more oral analgesics (84%
of visits) and more transdermal systems (5%) prescribed than
in patients with no or mild pain (50 and <1%, respectively).
Administration schedule
In 520 visits (51%), the analgesics were prescribed on a
regular schedule (by the clock). In 174 visits (17%), the
analgesics were only given on demand. Comparing be-
tween trials, the analgesics were prescribed most frequently
on a regular schedule in the first trial (in 58% of visits) and
least frequently in the fourth trial (42% of visits). In patients
indicating more than mild pain, analgesics were prescribed
more frequently on a regular schedule (71% of visits)
compared to patients with no or mild pain (35% of visits).
Summary evaluation
Treatment according to WHO criteria Overall, analgesic
treatment was sufficient according to the three WHO pain
treatment criteria (treatment according to one of the three
steps; oral, rectal, or transdermal application of the main
dose; administration on a regular schedule) in 345 visits
(34%). In further 349 visits (34%), at least one criterion was
not fulfilled. In patients indicating more than mild pain, we
observed a higher proportion of treatments according to the
WHO criteria (50% of visits) compared to patients with no
or mild pain (22% of visits). In 39% of the visits of patients
with more than mild pain, at least one criterion was not
fulfilled.
Table 1 Patient characteristics at baseline
SAKKa
Trial no.
Number
of patients
Previous radiotherapy
Yes/No
Bone metastases
Yes/No
Performance status
0-1/2-3
Median age (range)
years
08/91 28 14 (50%)/14 (50%) 24 (86%)/4 (14%) 11 (39%)/17 (61%) 68 (50–82)
08/93 30 10 (33%)/20 (67%) 29 (97%)/1 (3%) 24 (80%)/6 (20%) 72 (52–80)
08/95 43 19 (44%)/24 (56%) 41 (98%)/1 (2%) 31 (72%)/12 (28%) 69 (50–80)
08/97 44 23 (52%)/21 (48%) 38 (86%)/6 (14%) 36 (82%)/8 (18%) 71 (45–83)
08/00 25 12 (48%)/13 (52%) 24 (96%)/1 (4%) 21 (84%)/4 (16%) 70 (45–84)
Total 170 78 (46%)/92 (54%) 156 (92%)/13 (8%) 123 (72%)/47 (28%) 70 (45–84)
a Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung (Swiss Group for Clinical Cancer Research)
Table 2 Patient-rated pain intensity at baseline
SAKKa Trial no. No pain Mild pain Moderate pain Severe pain Data not available
08/91 3 (11%) 3 (11%) 8 (29%) 12 (43%) 2 (7%)
08/93 6 (20%) 4 (13%) 11 (37%) 8 (27%) 1 (3%)
08/95 5 (12%) 14 (33%) 16 (37%) 6 (14%) 2 (5%)
08/97 13 (30%) 12 (27%) 11 (25%) 7 (16%) 1 (2%)
08/00 2 (8%) 10 (40%) 5 (20%) 7 (28%) 1 (4%)
Total 29 (17%) 43 (25%) 51 (30%) 40 (24%) 7 (4%)
a Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung (Swiss Group for Clinical Cancer Research)
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Treatment according to Cleeland index Overall, in 636
visits (63%), there was a Cleeland index ≥0, indicating that
the prescribed class of analgesics was adequate for the
reported pain intensity. In 231 visits (23%), the Cleeland
index was <0, indicating that the prescribed analgesics were
inadequate for the reported pain intensity. In patients
indicating no or mild pain, the Cleeland index was ≥0 in
436 visits (87%) and <0 in 58 visits (12%). In patients
indicating more than mild pain, the Cleeland index was ≥0
in 190 visits (51%) and <0 in 170 visits (46%).
Insufficient pain treatment according to both WHO criteria
and Cleeland Index Overall, in 215 visits (21%), the three
WHO pain treatment criteria were fulfilled, and the Clee-
land index was ≥0, indicating adequate pain treatment
according to both requirements. In 59 visits (6%), neither
the WHO criteria were fulfilled nor was there a Cleeland
index ≥0 pointing to insufficient pain treatment: It did not
follow the WHO criteria, and the prescribed analgesics
were not sufficiently potent for the indicated pain intensity.
In 319 visits, one of these two requirements was not
fulfilled (WHO criteria not fulfilled in 233 visits or 23%,
Cleeland index <0 in 86 visits or 8%).
Discussion
We examined the quality of pain treatment in Swiss cancer
centers. The study is based on an analysis of five
multicenter phase II clinical trials on the palliative effect
of different chemotherapies in patients with advanced
hormone-refractory prostate carcinoma. In these patients,
pain is a common symptom, and the major treatment goal is
sufficient pain control. We examined only patients who
were treated at cancer centers. In such a selective sample,
we expected an optimal pain treatment.
It is difficult to judge the quality of pain treatment
because there is insufficient evidence from controlled trials
concerning adherence to the WHO guidelines [13]. Given
that the examined trials were designed for another, although
related purpose (i.e., palliative benefit by chemotherapy),
such a judgment would be even more difficult. However, it
was possible to investigate formal aspects which affect the
quality of the analgesic treatment. Our findings highlight
key aspects of cancer pain and its treatment in Switzerland
in the nineties.
During the chemotherapy period, there was a decrease
in patient-rated pain intensity: 50% of the patients
indicated no or mild pain on chemotherapy compared to
42% at baseline; 37% of patients indicated more than mild
pain on chemotherapy compared to 54% at baseline. It is
difficult to judge if these lower pain ratings during the
chemotherapy period compared to the baseline are due to
a better pain management at the cancer centers or to the
Table 3 Patient-rated pain intensity and treatment steps according to the WHO steps
Treatment steps No pain or mild
pain
Moderate pain or severe
pain
Data not
available
Total
No analgesics 217 (43%) 26 (7%) 28 (20%) 271 (27%)
Step 1 110 (22%) 119 (32%) 30 (21%) 259 (25%)
Step 2 29 (6%) 54 (14%) 14 (10%) 97 (10%)
Step 3 54 (11%) 101 (27%) 28 (20%) 183 (18%)
Treatment with weak or strong
opioids, no NSAIDa/Paracetamol
66 (13%) 63 (17%) 30 (21%) 159 (16%)
Only adjuvant drugs 24 (5%) 1 (<1%) 2 (1%) 27 (3%)
Not defined/missing 4 (<1%) 9 (2%) 8 (6%) 21 (2%)
Total 504 373 140 1017
a Non-steroidal anti-inflammatory drugs
Table 4 Shortcomings
Shortcomings
NSAIDa and/or paracetamol is prescribed in patients with substantial
pain instead of opioids
The dose of opioids is not adjusted when not sufficient
Opioids are not combined with NSAID or paracetamol
Opioids as basic medication, but the rescue medication for
breakthrough pain is an NSAID or paracetamol instead of an opioid
Rescue medication for breakthrough pain is a retard formulation
instead of an immediately effective preparation
The analgesic medication is reduced too rapidly, when pain is treated
successfully
Treatment with different drugs at one step instead of one medication
for each step
Different drugs for rescue medication instead of a sufficient basic
medication
a Non-steroidal anti-inflammatory drugs
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effect of the administered chemotherapies. Their palliative
benefit has been published elsewhere [15, 20–22, 24].
These figures are fairly consistent with those found in other
reports on patients with prostate cancer: In the study of
Calais da Silva et al. [3], 30% of patients at baseline and up
to 59% during the study indicated no pain, and only 28% of
patients in the study by Curran et al. [5] indicated quite a bit
or very much pain. Fosså et al. [9] described a higher
percentage: 55% of patients indicated quite a bit or very
much pain at baseline. Pollen and Schmidt [23] found an
even higher percentage of cancer patients with moderate or
severe pain. In the studies by Cleeland et al. [4], Dorrepaal
et al. [6], Brescia et al. [1], Larue et al. [18], and Zech et al.
[31] on patients with other cancers, 45–98% of patients
reported having pain.
The quality of the analgesic treatment yielded many
reassuring aspects. A substantial proportion of patients was
treated according to the WHO treatment steps: Many
patients received opioids (43% of all visits and 58% of
visits of patients with more than mild pain). Some authors
described a higher percentage: 45–80% [1, 6, 9, 18, 27, 31].
In a high number of the visits in which opioids were
prescribed, the opioids were combined with NSAID or
paracetamol (64%). Only Zech et al. [31] reported a higher
percentage of patients receiving the latter combination
(73%). Many patients (51% of all visits, 71% of visits of
patients indicating more than mild pain) received their
analgesics as a fixed medication (by the clock). In patients
with no or mild pain, administration of analgesics on
demand may be adequate. Our proportion of visits with
fixed medication is greater than in other reports: Vuorinen
et al. [28] reported 39–63% of patients with regularly
prescribed analgesics, Bruera et al. [2] 31–42%, Brescia et
al. [1] 36%. Most patients received their basic medication
as a peroral regime. In the more recent studies, we observed
an increase in the use of transdermal systems. Only in
exceptional cases was the basic medication administered
subcutaneously. These recommendations were less fre-
quently followed in patients with no or mild pain. The
Cleeland index, a conservative indicator for the adequacy of
the prescribed analgesics, was ≥0 in the majority of visits
(≥0 in 63%, <0 in 23% of all visits). Cleeland et al. [4]
described a higher number of cancer patients with a
negative index (42%) and Larue et al. [18] an even higher
number (51%). Surprisingly, we did not find a substantial
improvement in the quality of the analgesic treatment over
the decade when the SAKK trials were carried out.
Nevertheless, we identified deviations from the WHO
guidelines. They are summarized in Table 4. From other
studies, we know that a better treatment of cancer pain is
possible: Ventafridda et al. [27] reached a successful
treatment in 71% of patients by the adherence to the
WHO ladder. Zech et al. [31] described a good pain relief in
76%, a satisfactory efficacy in 12%, and inadequate
efficacy in only 12% of patients treated according to the
WHO guidelines. Jadad and Browman [13] concluded that
analgesia was adequate in 69–100% of the reviewed studies
using the WHO guidelines.
Based on our study, we cannot be fully satisfied with the
quality of pain treatment in Swiss cancer centers. This is a
multifaceted problem. A major problem consists of the
attitude towards cancer pain both of the patients and
physicians. Patients tend to underreport the experienced
pain [30], and many show reluctance to use opioids. Hence,
the problem cannot solely be solved by improving the
knowledge of the physicians; we need to intervene at
various levels. Solutions on a national level include
information campaigns to oppose the patients’ “opiopho-
bia”. On an institutional level, patients should be encour-
aged to report their pain, e.g., by a corresponding hospital
policy. To change the physicians’ attitude is also a
challenge. Education in Switzerland is good, but informa-
tion alone may not be sufficient to change the physicians’
practice [19]. National programs and institutional policies
must be promoted to make physicians aware of the
importance of analgesic treatment in cancer patients. Less
experienced colleagues need support from superiors or a
pain service. Institutions should promote the use of graphic
tools to make pain visible. Training programs should also
improve the physicians’ communication skills [8, 10, 19].
Conclusions
In this selective sample of patients with advanced prostate
cancer treated in Swiss cancer centers, we found a good
quality of analgesic treatment. However, further improve-
ment on a national and institutional level is required to
change the patients’ attitude towards cancer pain to
encourage patients to report their pain and to improve the
knowledge and communication skills of the physicians.
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